Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have earned a consensus rating of “Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $43.70.

URGN has been the subject of several analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a report on Friday, December 6th. Oppenheimer reissued an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a research report on Wednesday, October 16th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of UroGen Pharma in a research note on Tuesday, October 15th. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th.

UroGen Pharma Price Performance

URGN stock opened at $11.21 on Tuesday. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The business has a 50-day simple moving average of $11.73 and a two-hundred day simple moving average of $13.55. The company has a market capitalization of $262.92 million, a P/E ratio of -3.56 and a beta of 1.09. UroGen Pharma has a 52-week low of $10.26 and a 52-week high of $20.70.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to analysts’ expectations of $24.22 million. During the same period in the previous year, the firm earned ($0.68) EPS. Research analysts expect that UroGen Pharma will post -3.1 EPS for the current fiscal year.

Institutional Investors Weigh In On UroGen Pharma

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its holdings in UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock valued at $864,000 after purchasing an additional 49,318 shares during the period. Tidal Investments LLC lifted its position in shares of UroGen Pharma by 19.1% during the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock valued at $477,000 after buying an additional 6,030 shares during the last quarter. Barclays PLC grew its stake in shares of UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after acquiring an additional 48,040 shares during the period. Geode Capital Management LLC increased its holdings in UroGen Pharma by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock worth $5,787,000 after acquiring an additional 34,248 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in UroGen Pharma in the 3rd quarter valued at about $297,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.